JP2023502323A5 - - Google Patents
Info
- Publication number
- JP2023502323A5 JP2023502323A5 JP2022524620A JP2022524620A JP2023502323A5 JP 2023502323 A5 JP2023502323 A5 JP 2023502323A5 JP 2022524620 A JP2022524620 A JP 2022524620A JP 2022524620 A JP2022524620 A JP 2022524620A JP 2023502323 A5 JP2023502323 A5 JP 2023502323A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- chain variable
- variable region
- pharmaceutical combination
- combination product
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNPCT/CN2019/120033 | 2019-11-21 | ||
| CN2019120033 | 2019-11-21 | ||
| PCT/CN2020/129992 WO2021098757A1 (en) | 2019-11-21 | 2020-11-19 | Methods of cancer treatment using anti-ox40 antibodies in combination with anti-tigit antibodies |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023502323A JP2023502323A (ja) | 2023-01-24 |
| JP2023502323A5 true JP2023502323A5 (https=) | 2023-11-29 |
Family
ID=75980305
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022524620A Pending JP2023502323A (ja) | 2019-11-21 | 2020-11-19 | 抗ｔｉｇｉｔ抗体との組合せで抗ｏｘ４０抗体を用いる癌治療の方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20230002500A1 (https=) |
| EP (1) | EP4061846A4 (https=) |
| JP (1) | JP2023502323A (https=) |
| KR (1) | KR20220103709A (https=) |
| CN (1) | CN114746446A (https=) |
| AU (1) | AU2020385499A1 (https=) |
| BR (1) | BR112022009265A2 (https=) |
| CA (1) | CA3157042A1 (https=) |
| IL (1) | IL293118A (https=) |
| MX (1) | MX2022006148A (https=) |
| WO (1) | WO2021098757A1 (https=) |
| ZA (1) | ZA202204422B (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112020023746A2 (pt) | 2018-05-23 | 2021-02-17 | Beigene, Ltd. | anticorpo, composição farmacêutica, método para tratar câncer, ácido nucleico isolado, vetor, célula hospedeira, processo para a produção de um anticorpo e reagente de diagnóstico |
| TW202216778A (zh) | 2020-07-15 | 2022-05-01 | 美商安進公司 | Ｔｉｇｉｔ及ｃｄ１１２ｒ阻斷 |
| CA3261847A1 (en) * | 2022-07-15 | 2024-01-18 | Beigene Switzerland Gmbh | CANCER TREATMENT METHODS USING ANTI-TIGIT ANTIBODIES |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2439273T3 (da) * | 2005-05-09 | 2019-06-03 | Ono Pharmaceutical Co | Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika |
| SG10202112838YA (en) * | 2008-04-09 | 2021-12-30 | Genentech Inc | Novel compositions and methods for the treatment of immune related diseases |
| SG10201708048XA (en) * | 2013-03-18 | 2017-10-30 | Biocerox Prod Bv | Humanized anti-cd134 (ox40) antibodies and uses thereof |
| KR20170066546A (ko) * | 2014-10-03 | 2017-06-14 | 노파르티스 아게 | 조합 요법 |
| TW201619200A (zh) * | 2014-10-10 | 2016-06-01 | 麥迪紐有限責任公司 | 人類化抗－ｏｘ４０抗體及其用途 |
| US20160152720A1 (en) * | 2014-11-06 | 2016-06-02 | Genentech, Inc. | Combination therapy comprising ox40 binding agonists and tigit inhibitors |
| DK3303396T5 (da) * | 2015-05-29 | 2024-10-07 | Bristol Myers Squibb Co | Antistoffer mod ox40 og anvendelser deraf |
| GB201519481D0 (en) * | 2015-11-04 | 2015-12-16 | Cancer Rec Tech Ltd | Immunomodulatory antibodies |
| IL272227B2 (en) * | 2017-07-27 | 2025-09-01 | iTeos Belgium SA | Anti-tigit antibodies |
| JP2021501801A (ja) * | 2017-11-01 | 2021-01-21 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | 癌の処置に用いるための免疫刺激アゴニスト抗体 |
| EP3713958A4 (en) * | 2017-11-24 | 2021-11-03 | Eucure (Beijing) Biopharma Co., Ltd | ANTI-OX40 ANTIBODIES AND USES THEREOF |
| TWI877769B (zh) * | 2017-12-30 | 2025-03-21 | 英屬開曼群島商百濟神州有限公司 | 抗tigit抗體及其作為治療和診斷的用途 |
| CN111393529B (zh) * | 2018-01-29 | 2022-02-22 | 康源博创生物科技(北京)有限公司 | 与ox40l非竞争结合的抗ox40抗体 |
| BR112020023746A2 (pt) * | 2018-05-23 | 2021-02-17 | Beigene, Ltd. | anticorpo, composição farmacêutica, método para tratar câncer, ácido nucleico isolado, vetor, célula hospedeira, processo para a produção de um anticorpo e reagente de diagnóstico |
-
2020
- 2020-11-19 US US17/778,660 patent/US20230002500A1/en not_active Abandoned
- 2020-11-19 WO PCT/CN2020/129992 patent/WO2021098757A1/en not_active Ceased
- 2020-11-19 JP JP2022524620A patent/JP2023502323A/ja active Pending
- 2020-11-19 KR KR1020227014833A patent/KR20220103709A/ko active Pending
- 2020-11-19 CA CA3157042A patent/CA3157042A1/en active Pending
- 2020-11-19 AU AU2020385499A patent/AU2020385499A1/en active Pending
- 2020-11-19 IL IL293118A patent/IL293118A/en unknown
- 2020-11-19 CN CN202080080865.7A patent/CN114746446A/zh active Pending
- 2020-11-19 BR BR112022009265A patent/BR112022009265A2/pt unknown
- 2020-11-19 MX MX2022006148A patent/MX2022006148A/es unknown
- 2020-11-19 EP EP20889442.8A patent/EP4061846A4/en not_active Withdrawn
-
2022
- 2022-04-20 ZA ZA2022/04422A patent/ZA202204422B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024037894A5 (https=) | ||
| JP2024020298A5 (https=) | ||
| JP2020528750A5 (https=) | ||
| CN110536903A (zh) | 抗ox40抗体及其用途 | |
| IL276830B2 (en) | Anti-claudin 18.2 antibodies and uses thereof | |
| JP2021531005A5 (https=) | ||
| RU2019111722A (ru) | Антитела против siglec-15 и способы их применения | |
| JP2023503396A5 (https=) | ||
| JP2021527431A5 (https=) | ||
| IL318482A (en) | Pd-1 inhibitor for use in a method of treating skin cancer | |
| JP2021531764A5 (https=) | ||
| IL276695A (en) | Antibodies, pharmaceutical compositions and uses thereof | |
| JP2020515247A5 (https=) | ||
| JP2017535257A5 (https=) | ||
| JP2020514310A5 (https=) | ||
| JP2022533538A5 (https=) | ||
| CN112513094A (zh) | 结合人her2的抗体、其制备方法和用途 | |
| CN111278861A (zh) | Pd-l1抗体、其抗原结合片段及医药用途 | |
| JP2023543152A5 (https=) | ||
| RU2019104980A (ru) | Анти-icos антитела | |
| JP2023502323A5 (https=) | ||
| JP2024540148A5 (https=) | ||
| JP2021512652A5 (https=) | ||
| JP2024504331A5 (https=) | ||
| JP2022519631A5 (https=) |